Innate Pharma: Update on capital and voting rights

Innate Pharma SA, a company listed on Euronext Paris and Nasdaq, has announced the number of shares comprising its capital and the associated voting rights as of September 1, 2025. The ordinary shares total 92,185,473, supplemented by 6,419 2016 Preferred Shares and 7,581 2017 Preferred Shares.

The number of theoretical voting rights is set at 92,962,943, while the number of exercisable voting rights amounts to 92,944,368. This information is disseminated in accordance with the rules of the French Commercial Code and the recommendations of the Financial Markets Authority. This count takes into account treasury shares, which are deprived of voting rights.

The company continues to focus on developing innovative immunotherapy treatments, maintaining important partnerships with biopharmaceutical leaders.